Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years

More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news148054334.html">Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years</a></p> <p>More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.</p>